Target
IL-18
2 abstracts
Abstract
Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells.Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Center for Cellular Immunotherapies, Department of Biostatistics, Epidemiology, and Informatics,
Abstract
Diagnostic and prognostic biomarker value of blood circulating inflammatory cytokines in hepatocellular carcinoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center,